Literature DB >> 1529737

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.

A L Nyth1, C G Gottfries, K Lyby, L Smedegaard-Andersen, J Gylding-Sabroe, M Kristensen, H E Refsum, E Ofsti, S Eriksson, S Syversen.   

Abstract

A total of 149 patients in 7 centers in Denmark, Norway and Sweden entered a 6-week double-blind trial intended to assess the antidepressant effect and safety of citalopram vs placebo in depressed elderly patients (65 years of age or older) who might also suffer from somatic disorders and/or senile dementia. Results of ratings on the Hamilton Rating Scale for Depression, the Montgomery-Asberg Depression Rating Scale and the Clinical Global Impression Scale provided consistent evidence that the citalopram-treated patients improved more than the placebo-treated patients. Results of ratings on the Gottfries-Bråne-Steen dementia rating scale indicated that both cognitive and emotional functioning improved significantly more in the citalopram-treated subgroup of patients with dementia than in the placebo-treated subgroup.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1529737     DOI: 10.1111/j.1600-0447.1992.tb03242.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  37 in total

1.  Antidepressants for old people. GPs should become familiar with one or two antidepressants from each class.

Authors:  R C Baldwin
Journal:  BMJ       Date:  1999-09-25

2.  New antidepressants for old people?

Authors:  M G Livingston; H M Livingston
Journal:  BMJ       Date:  1999-06-19

3.  Measuring symptoms of depression: comparing the Cornell Scale for Depression in Dementia and the Patient Health Questionnaire-9-Observation Version.

Authors:  Lorraine J Phillips
Journal:  Res Gerontol Nurs       Date:  2011-12-14       Impact factor: 1.571

4.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

5.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 6.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 7.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 8.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics.

Authors:  Simon W Rabkin
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

10.  Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression.

Authors:  Johanna Ulfvarson; Johanna Adami; Regina Wredling; Bengt Kjellman; Marie Reilly; Christer von Bahr
Journal:  Eur J Clin Pharmacol       Date:  2003-11-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.